FDA Panel Votes Sufficient Evidence Available to Support EFS

In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.

Related Keywords

United States , Los Angeles , Shahab Asgharzadeh , Aerang Kim , Children National Hospital , Oncologic Drugs Advisory Committee , Oncologic Drugs Advisory Committee Meeting , Roswell Park Comprehensive Cancer Institute , Translational Program , Division Of Hematology , Drugs Advisory Committee , Yirang Kim , National Hospital , Associate Professor , Neuroblastoma Basic , Marrow Transplantation , Keck School , Eflornithine , Pediatric Patients With High Risk Neuroblastoma , D , Phd , Childrens National Hospital , Childrens Hospital Of Los Angeles , Keck School Of Medicine The University Southern California , Clare Twist ,